Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00491855 · ClinicalTrials.gov registry record · Phase 1

Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis

A Phase 1 study of Peritoneal Cancer, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 1
Development phase
3
Enrollment target
1
Study location

NCT00491855: Completed Phase 1 study of Peritoneal Cancer, sponsored by M.D. Anderson Cancer Center.

NCT00491855 is a Phase 1 study of Peritoneal Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 3 participants, below the 154-participant average among 32 other Peritoneal Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00491855, a Phase 1 study of Peritoneal Cancer, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
3 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical research is to learn acceptable dosages of paclitaxel, oxaliplatin, and Avastin (bevacizumab) that can be given in combination to patients with advanced peritoneal carcinomatosis. The safety of this drug combination will also be studied.

Conditions Studied

Interventions

  • DRUG Bevacizumab
  • DRUG Oxaliplatin
  • DRUG Paclitaxel

Study Locations (1)

Texas

  • U.T.M.D. Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2007-06
Est. Completion 2012-12
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT00491855

The ClinicalTrials.gov registry entry for NCT00491855 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 154-participant average among 32 other Peritoneal Cancer trials with a reported enrollment target (98% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Peritoneal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.

NCT00491855 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00491855 about?

NCT00491855 is a clinical study titled "Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis". The goal of this clinical research is to learn acceptable dosages of paclitaxel, oxaliplatin, and Avastin (bevacizumab) that can be given in combination to patients with advanced peritoneal carcinomatosis. The safety of this drug combination will also be studied.

What is the current status of trial NCT00491855?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2007-06. Estimated completion is 2012-12.

What conditions does trial NCT00491855 study?

This clinical trial studies the following conditions: Peritoneal Cancer.

What interventions are being tested in trial NCT00491855?

The interventions under investigation include: Bevacizumab (DRUG), Oxaliplatin (DRUG), Paclitaxel (DRUG).

Who is sponsoring clinical trial NCT00491855?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00491855 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peritoneal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.